潜江永安药业股份有限公司关于与全资子公司湖北凌安科技有限公司签订《吸收合并协议》及通知债权人的公告

Group 1 - The core point of the announcement is that Qianjiang Yong'an Pharmaceutical Co., Ltd. has signed an absorption merger agreement with its wholly-owned subsidiary Hubei Ling'an Technology Co., Ltd. to optimize management structure and improve operational efficiency [2][3] - The merger will result in the cancellation of Ling'an Technology's legal entity, with all assets, debts, and rights being inherited by Yong'an Pharmaceutical [2][4] - The merger will not affect the company's name, registered capital, shareholding structure, or changes in the board of directors and senior management [2][3] Group 2 - The merger is set to take effect on the completion date, which will be determined after fulfilling internal decision-making procedures, signing the merger agreement, and obtaining necessary government approvals [3][4] - The registered capital of Yong'an Pharmaceutical before the merger is RMB 294,682,500, while Ling'an Technology's registered capital is RMB 16,670,000. Post-merger, Yong'an's registered capital remains unchanged [7] - The merger process includes notifying creditors, publishing merger announcements, and completing necessary legal and administrative procedures [8][9] Group 3 - Creditors have the right to claim debts or request guarantees within thirty days of receiving notification or within forty-five days from the announcement if no notification is received [12] - Specific documentation is required for creditors to assert their claims, including identification and authorization documents [13][14] - The merger agreement and related documents will be available for review [15]